1984results about How to "Reduce aggregation" patented technology

The present invention relates generally to the field of high content screening of particles, e.g., cells in a flow cytometric system. In particular, the present invention relates to devices, methods and systems to obtain line-scan images of particles, e.g., cells, of a plurality of different samples simultaneously, where the line-scan images can be used to identify cells based on at least one of a variety of phenotypic characteristics such as shape, asymmetry, and intracellular information for cell sorting and selection. In some embodiments, the line-scan images are obtained as the particles, e.g., cells, in a plurality of different samples flow through a plurality of microchannels, reducing the need and time for focusing of the image detection system. In some embodiments, the laser spot size has a small spatial resolution for rapid capturing of images of cells. In some embodiments, the laser spot size has a larger spatial resolution for imaging of larger particles or cells, e.g., rare cells in a sample. In some embodiments, the devices, methods and systems are automated for a high-throughput, high content screening of particles such as cells in a plurality of samples.

Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.

A method of stenting, comprises: implanting a stent assembly in a vessel of a subject, the stent assembly, including: a stent jacket, comprising an expansible mesh structure, formed of fibers of a diameter between about 7 micrometers and about 18 micrometers, the diameter having a property of forming a substantially stable layer of endothelial cells, covering the fibers, thus reducing platelet aggregation, and an expansible stent, operatively associated with the stent jacket. The method further comprises administering to the subject an active pharmaceutical ingredient (API) comprising a platelet aggregation reducer for a shortened time period, not exceeding six months, the shortened time period being a consequence of the property. In accordance with some embodiments, the administration of a platelet aggregation.

Biocompatible polymeric materials capable of providing in situ release of nitric oxide (NO) included diazeniumdiolated fumed silica as a filler in a multilayer polymer structure to release NO upon contact with water (blood). The blood-contacting polymer surface is preferably multi-layered so that the NO-releasing layer, containing the diazeniumdiolated fumed silica, is shielded from blood contact by one or more top (or base) coats. When in contact with blood, the NO released at the surface of the polymer prevents platelet activation and adhesion to the surface, thereby reducing platelet consumption, risk of thrombus formation and other clinical complications associated with interactions between blood and foreign materials.

An object of the invention is to provide a negative electrode for a nonaqueous electrolyte secondary battery having a small surface film resistance and a high negative electrode strength. The present invention relates to a negative electrode for a nonaqueous electrolyte secondary battery, wherein an active material layer containing an active material and a binder is formed on a collector, the active material being a material in which metal oxide fine particles having an average particle diameter of 250 nm or less are attached to the surface and the binder being a binder having an olefinic unsaturated bond.

Disclosed herein are methods and compositions for treating or preventing Huntington's Disease.

A process for preparing low-carbon olefin from methanol or dimethyl ether includes loading its raw material and silicon aluminium phosphate (SAPO34) molecular sieve as catalyst into gas-solid parallel down-flowing fluidized bed reactor, super-short contact, reaction, fast gas-solid separation to separating resultant from catalyst to prevent secondary reaction, and regerating catalyst for cyclic use. Its advantages include high output rate (93%), high conversion rate of raw material, and less by-product.

A method of chemically modifying carbon nanotubes having a diameter less than one micron comprising: contacting the nanotubes with a peroxygen compound selected from the group consisting of organic peroxyacids, inorganic peroxoacids and organic hydroperoxides, or a salt thereof, under oxidation conditions and thereby producing modified carbon nanotubes. Oxidation of the nanotubes increases the degree of dispersion of aggregates of nanotubes and aids in the disassembling of such aggregates. The dispersed nanotubes are used to prepare rigid structures and can be used in electrodes and capacitors.

A method of treating a mammal with a formulation comprising an antibody which binds IgE as described.

A method of reducing packet congestion at a network node in a packet-switched data communication network, which method comprises the steps of marking one or more packets in said queue, wherein a probability of marking a packet in the queue is higher for a first proportion of the packets than for a second proportion of the packets, one or more packets of said first proportion having spent less time on said network than one or more packets of said second proportion.

The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example amylin, a monoclonal antibody, insulin, Peptide T or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof.

A method for preparing transparent mesostructured inorganic/block-copolymer composites or inorganic porous solids containing optically responsive species with selective optical, optoelectronic, and sensing properties resulting therefrom. Mesoscopically organized inorganic/block copolymer composites doped with dyes or complexes are prepared for use as optical hosts, chemical/physical/biological sensors, photochromic materials, optical waveguides, tunable solid-state lasers, or optoelectronic devices. The materials can be processed into a variety of different shapes, such as films, fibers, monoliths, for novel optical and sensing applications.

The invention relates to a refined crystal grain aluminum alloy and the manufacturing method. It is made up from Si 0.2-7.5wt%, Mn 0.05-1.5wt%, Mg 0,05-6.0wt%, Zn 0.03-8.5wt%, Cu 0.05-7.0wt%, Ni 0.1-2.5wt%, Ti 0.01-0.15wt%, RE 0.01-0.3wt%, B 0.0001-0.10wt%, and the rest is Al. The technology feature is that it adds silicon titanium alumina, borax and or rare earth oxide or rare earth carbonate, or titanium oxide, borax and/or rare earth oxide or rare earth carbonate into aluminum cell. Add the manganese oxide, compound of copper or Ni would be also added. Comparing to traditional technology, the refiner is not added, and the refining effect is enhanced and the perdurability is prolonged. It could be used to produce wire, band, tube, panel, aluminum foil, etc.

The present invention relates to bone cements and, more particularly, to multi-solution bone cements and methods for making the same. An embodiment of the present invention provides multi-solution bone cements which include cross-linked PMMA beads, thereby providing for a significant increase in the polymer-to-monomer (P:M) ratio. Another embodiment of the present invention provides cross-linked PMMA beads which are surface modified with unsaturated carbon double bonds. A further embodiment of the present invention provides multi-solution bone cements made with PMMA-PMMA spherical brush polymers.

Disclosed are Fc-interferon-beta (Fc-IFN-β) fusion proteins and nucleic acid molecules encoding them. The Fc-IFN-β fusion proteins include variants of the interferon-beta (IFN-β) protein that are altered to achieve enhanced biological activity, prolonged circulating half-life and greater solubility. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins and/or nucleic acid molecules for treating diseases and conditions alleviated by the administration of interferon-beta.